We complete the post-procedural compression process by enabling Patent Hemostasis from minute one.
Defining
Guided Compression
IDAHealth completes the post-procedural transradial compression process by enabling Patent Hemostasis from minute one.
Patent Hemostasis (stopping the bleed while maintaining radial artery flow) is the recommended clinical standard of every major cardiology society. The clinical evidence base started with the PROPHET trial in 2008 and has been reinforced by every subsequent guideline cycle. Formal society consensus crystallized over the last seven years, beginning with SCAI in 2019, followed by ACC/AHA in 2021, ESC in 2022, BCIS and CSI in 2025, and DGK in 2026. The standard is still achieved inconsistently because the tool to measure it in real time does not exist. Compression bands are applied blindly. Nurses check intermittently.
We built that tool. IdaFlo TR is a non-sterile, single-use Class II wristband that monitors radial flow continuously during compression. Patent Hemostasis becomes a measured operating state, not an aspiration. Shorter hemostasis time, lower nursing labor, faster same-day discharge, and a preserved radial artery for life are the consequences. Reduced Radial Artery Occlusion is one of those consequences, not the entire reason to care.
Patency also matters for the patient in the weeks and months immediately after the procedure. Despite collateral flow from the ulnar artery, occluded radial arteries can produce upper-limb symptoms ranging from mild discomfort to clinically significant complaints (Wiper et al., Catheter Cardiovasc Interv 2019). Patent Hemostasis from minute one is therefore not only about preserving the artery for the next procedure. It is about preserving normal upper-limb circulation for the patient living with it.
Patent Hemostasis is the recommended clinical standard now endorsed by every major cardiology society. It reduces complications and, as demonstrated by Takamatsu et al. (2023, n=1,842 patients), shortens hemostasis time from 190 to 66 minutes. The 2026 DGK position paper (Breitbart et al., Kardiologie 2026;20:54-61) recommends Patent Hemostasis as the central prevention strategy and describes only manual, intermittent verification methods (pulse oximetry, reversed Barbeau, visual checks). RAO incidence remains approximately 13 percent across 30,000+ patients in a meta-analysis of 41 studies (Khalid et al. 2024) despite current practice. Continuous, real-time flow monitoring is not addressed.
IdaFlo TR closes that gap. Powered by the IDASense conductive-elastomer sensor platform, it converts the post-procedural compression process from operator inference into a measured, auditable workflow. Centers of Excellence in the Netherlands, Belgium, Germany, and the United Kingdom are advancing the standard today.
Why We Started, and Why Now
IDAHealth was founded around a single observation by Co-Founder and Medical Director Dr. Giovanni Amoroso (OLVG Amsterdam, The Netherlands): Patent Hemostasis was already a recommended best practice in published clinical literature, yet inconsistently achieved at the bedside. The first IdaFlo TR clinical test ran at OLVG in February 2018. Society-level consensus crystallized in the years that followed. At the time of founding, the integrated low-power wireless and sensing electronics required for a true single-use disposable wristband were too large and too expensive to deliver at the price point a cath lab can absorb. We waited for the technology to catch up to the clinical need. The cost and size gap has now closed, society consensus is now universal, and we are completing the MVP today.
Our Mission
To make Patent Hemostasis effortless after every transradial procedure. To turn the published clinical standard into a measured operating state. To preserve the radial artery for the procedures patients have not had yet.
Our Vision
Guided Compression as the universal practice standard wherever transradial access is used. Real-time flow confirmation for every compression. Radial access preserved across a patient's lifetime and across every specialty that needs it.
David L. Camp, Jr
With 25+ years of experience in medical device innovation, specializing in corporate operations, business development, sales, and marketing. Served as CEO of Orbus Medical Technologies (acquired by
OrbusNeich). Holder of numerous international and US patents.
Danny de Vries
Expert in steering the development of cutting-edge medical devices and systems, with a proven track record in managing complex R&D initiatives.
Rob de Ree
Rob de Ree served as CEO of Dezima Pharma (acquired by Amgen) and BMEYE (acquired by Edwards Lifesciences). He previously held leadership roles at Crucell, Medtronic, and Byk Gulden. Currently, he is a board member at Sirius Medical and an operating partner at Biogeneration Ventures. Rob holds a PharmD from the University of Groningen.
Kees Kolff
After a successful management buy out of a global business solutions company, ADM Group, Kees managed operations across EMEA and Asia before returning to Europe to take on the role of Executive Director. In this capacity, he focused on business development and M&A. Currently, he serves as an ambassador for ADM Group and as Chairman of the Board for one of its subsidiaries, ADM 360, a specialized solutions company within the hospitality industry.
Board of Directors
Scientific Advisory Board
Dr. G. Amoroso, MD, PhD
Medical Director, OLVG Hospital
Key Opinion Leader in transradial
coronary procedures and miniaturization of interventional devices.
Co-Founder and Medical Director IDAHealth
Prof. Stephane Carlier
University of Mons (UMONS)
Chief of Cardiology and Interventional Cardiologist at University Hospital Helora (Mons, Belgium) and Professor at UMons. An expert in complex coronary interventions, and AI in atrial fibrillation prediction, he also founded Coeur CoreLab and serves on advisory boards and journal review panels.
Dr. Jim Nolan
Keele University, United Kingdom
Professor James Nolan is a KOL in the field of optimized vascular access practice, with a strong track record of research, education, and training in trans-radial procedures
After a successful management buy out of a global business solutions company, ADM Group, Kees managed operations across EMEA and Asia before returning to Europe to take on the role of Executive Director. In this capacity, he focused on business development and M&A. Currently, he serves as an ambassador for ADM Group and as Chairman of the Board for one of its subsidiaries, ADM 360, a specialized solutions company within the hospitality industry.
Kees Kolff
Chief Commercial Officer
With a career span over more than two decades, Niels held key roles in various industries, including medical devices, leisure, and consultancy. He holds a Master’s degree in Marketing Management from Erasmus University, Rotterdam. Next to his main focus marketing, he is also experienced in operations, logistics, and customer service.
Niels Teeuwen
Director of Marketing
David L. Camp, Jr
CEO and Co-Founder
With 25+ years of experience in medical device innovation, specializing in corporate operations, business development, sales, and marketing. Served as CEO of Orbus Medical Technologies (acquired by
OrbusNeich). Holder of numerous international and US patents.
Lucien van Os
Chief Technology Officer
Luciën is globally recognized for his medical device technology leadership at Medtronic, Gambro/Baxter, Sphere Medical, TMSi, Philips, and Ericsson.
Marcel Haan
Chief Operating Officer
With 30 years of MedTech experience spanning R&D, regulatory affairs, supply chain, and commercial operations, Marcel was employee #1 at OrbusNeich BV, where he helped scale the company from startup to €80M in revenue and a multi-million dollar exit. He has built and directed distribution networks across 55+ countries and holds an Engineering degree in Precision Mechanics and an MBA.